NVAX
$9.62-0.12 (-1.23%)
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally.
Recent News
Novavax (NVAX) Stock Moves -1.23%: What You Should Know
Novavax (NVAX) closed at $9.62 in the latest trading session, marking a -1.23% move from the prior day.
3 Profitable Stocks That Concern Us
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Assessing Novavax (NVAX) Valuation After Surprise Q4 Profitability And New Pfizer Licensing Deal
Novavax (NVAX) is back in focus after Q4 2025 results showed surprise profitability, with revenue of US$147.14 million and net income of US$17.53 million, supported by key vaccine partnerships and milestone payments. See our latest analysis for Novavax. The latest earnings surprise has come after a sharp move in the share price, with a 1 day share price return of a 9.38% decline following a strong 90 day share price return of 43.83% and a 1 year total shareholder return of 21.73%. However,...